Renaissance Technologies's FATE Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 2.36 M shares of Fate Therapeutics, Inc. (FATE) worth $2.32 M, representing 0.00% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in FATE, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 1.27 M shares. Largest reduction occurred in Q2 2023, reducing 660,603 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Fate Therapeutics (FATE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fate Therapeutics (FATE) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2015 | +14,900 | New Buy | 14,900 | $4.90 |
| Q2 2015 | +65,820 | Add 441.74% | 80,720 | $6.47 |
| Q3 2015 | +11,880 | Add 14.72% | 92,600 | $5.33 |
| Q4 2015 | -4,100 | Reduce 4.43% | 88,500 | $3.37 |
| Q1 2016 | +134,200 | Add 151.64% | 222,700 | $1.80 |
| Q2 2016 | -42,000 | Reduce 18.86% | 180,700 | $1.70 |
| Q3 2016 | +7,300 | Add 4.04% | 188,000 | $3.12 |
| Q4 2016 | +21,900 | Add 11.65% | 209,900 | $2.51 |
| Q1 2017 | +85,800 | Add 40.88% | 295,700 | $4.55 |
| Q2 2017 | +13,100 | Add 4.43% | 308,800 | $3.24 |
| Q3 2017 | -88,900 | Reduce 28.79% | 219,900 | $3.96 |
| Q4 2017 | -74,700 | Reduce 33.97% | 145,200 | $6.11 |
| Q1 2018 | -105,100 | Reduce 72.38% | 40,100 | $9.75 |
| Q2 2018 | -40,100 | Sold Out | 0 | $0.00 |
| Q3 2018 | +95,100 | New Buy | 95,100 | $16.29 |
| Q4 2018 | -95,100 | Sold Out | 0 | $0.00 |
| Q1 2019 | +79,662 | New Buy | 79,662 | $17.57 |
| Q2 2019 | -67,843 | Reduce 85.16% | 11,819 | $20.31 |
| Q3 2019 | -11,819 | Sold Out | 0 | $0.00 |
| Q3 2020 | +51,619 | New Buy | 51,619 | $39.97 |
| Q4 2020 | -51,619 | Sold Out | 0 | $0.00 |
| Q2 2021 | +34,719 | New Buy | 34,719 | $86.78 |
| Q3 2021 | -34,719 | Sold Out | 0 | $0.00 |
| Q1 2022 | +45,319 | New Buy | 45,319 | $38.77 |
| Q2 2022 | -45,319 | Sold Out | 0 | $0.00 |
| Q3 2022 | +537,519 | New Buy | 537,519 | $22.41 |
| Q4 2022 | +1.27 M | Add 235.79% | 1.8 M | $0.01 |
| Q1 2023 | -472,017 | Reduce 26.15% | 1.33 M | $0.01 |
| Q2 2023 | -660,603 | Reduce 49.56% | 672,316 | $0.00 |
| Q3 2023 | -563,097 | Reduce 83.75% | 109,219 | $2.12 |
| Q4 2023 | -109,219 | Sold Out | 0 | $0.00 |
| Q2 2024 | +548,544 | New Buy | 548,544 | $3.28 |
| Q3 2024 | -185,925 | Reduce 33.89% | 362,619 | $3.50 |
| Q4 2024 | +16,000 | Add 4.41% | 378,619 | $1.65 |
| Q1 2025 | -378,619 | Sold Out | 0 | $0.00 |
| Q2 2025 | +214,463 | New Buy | 214,463 | $1.12 |
| Q3 2025 | +1.05 M | Add 488.69% | 1.26 M | $1.26 |
| Q4 2025 | +1.1 M | Add 87.00% | 2.36 M | $0.98 |
Renaissance Technologies's Fate Therapeutics Investment FAQs
Renaissance Technologies first purchased Fate Therapeutics, Inc. (FATE) in Q1 2015, acquiring 14,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Fate Therapeutics, Inc. (FATE) for 38 quarters since Q1 2015.
Renaissance Technologies's largest addition to Fate Therapeutics, Inc. (FATE) was in Q4 2022, adding 1,804,936 shares worth $18,212.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 2,360,881 shares of Fate Therapeutics, Inc. (FATE), valued at approximately $2.32 M.
As of the Q4 2025 filing, Fate Therapeutics, Inc. (FATE) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Fate Therapeutics, Inc. (FATE) was 2,360,881 shares, as reported at the end of Q4 2025.